Benitec Biopharma Inc. Retained Earnings
Benitec Biopharma Inc. (BNTC) had Retained Earnings of -$273.72 million as of 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-09-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$273.72M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$260.91M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$248.98M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$237.14M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$273.72M 10-K · filed 2026-09-14 | |
| 2026-03-31 | -$260.91M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | -$248.98M 10-Q · filed 2026-02-12 | |
| 2025-09-30 | -$237.14M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$228.18M 10-K · filed 2026-09-14 | |
| 2025-03-31 | -$212.03M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$202.68M 10-Q · filed 2025-02-14 | |
| 2024-09-30 | -$195.32M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$190.26M 10-K/A · filed 2026-03-20 | |
| 2024-03-31 | -$185.54M 10-K · filed 2024-09-26 | -$184.92M 10-Q · filed 2024-05-13 |
| 2023-12-31 | -$181.26M 10-K · filed 2024-09-26 | -$180.64M 10-Q · filed 2024-02-13 |
| 2023-09-30 | -$174.46M 10-K · filed 2024-09-26 | -$173.84M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$167.89M 10-K · filed 2024-09-26 | |
| 2023-03-31 | -$163.23M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$158.83M 10-Q · filed 2023-02-13 | |
| 2022-09-30 | -$153.42M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$148.33M 10-K · filed 2023-09-21 | |
| 2022-03-31 | -$143.26M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$139.99M 10-Q · filed 2022-02-14 | |
| 2021-09-30 | -$135.16M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$130.12M 10-K · filed 2022-09-02 | |
| 2021-03-31 | -$126.12M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | -$122.21M 10-Q · filed 2021-02-09 | |
| 2020-09-30 | -$119.34M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | -$116.64M 10-K · filed 2021-09-20 | |
| 2019-06-30 | -$108.87M 10-K · filed 2020-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |